Considering the fact that these genes are often carried on mobile genetic elements and could easily be spread among the members of Enterobacteriaceae
, such information is needed for choosing a proper antibiotic therapy and may prevent the dissemination of these resistance determinants among important Gram-negative pathogens.
3), p(j) is the fixed effect of time (total Enterobacteriaceae
counts: j = 1, 2; blend recovery: j = 0, .
Multiplex Polymerase Chain Reaction (PCR) Assays For The Detection of Enterobacteriaceae
In Clinical Samples.
16) found that poor functional status, current antibiotic use, chronic renal insufficiency, liver disease and use of histamine 2-receptor antagonists were the independent risk factors for fecal carriage; their study included a wide range of ESBL-producing Enterobacteriaceae
, and one-third of their patients were from a long-term care facility.
A total of 239 consecutive, non-repetitive, clinical isolates of Enterobacteriaceae
isolated from various clinical samples such as exudates (95), urine (71), sputum (54), blood (15) and vaginal swab (4) obtained between July 2009 and November 2009 were included in the study.
Simple rank-ordering of the mean bacterial counts of drinking-water, SRP, LB, and traditional complementary foods showed similar trends for aerobic bacteria, coliform and Enterobacteriaceae
Evaluation of the BD Phoenix automated microbiology system for identification and antimicrobial susceptibility testing of Enterobacteriaceae
in general, and Salmonella in particular, have been found variably resistant to ampicillin, chloramphenicol, tetracyclines and sulfonamides in humans for several years (Molbak et al.
Gram-negative isolates were classified as Enterobacteriaceae
based on their listing in a standard microbiological text and as non-Enterobacteriaceae
if they were not in this list.
This report provides information on the therapeutic development for Enterobacteriaceae
Infections, complete with latest updates, and special features on late-stage and discontinued projects.
Food and Drug Administration (FDA) has accepted for review the Company's New Drug Application (NDA) for plazomicin for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis, and bloodstream infections (BSI) due to certain Enterobacteriaceae
in patients who have limited or no alternative treatment options.
Results: Significantly decreased Akkermansia muciniphila and increased Enterobacteriaceae
levels were determined in patients compared to healthy controls even after adjusting for the body mass index (BMI) and age.